Development of vaccines for preventing and treating disease
EpiVax is a privately held company based in Providence, RI. We are dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry.
EpiVax intends to utilize its scientific and technological assets related to epitope discovery, de-immunization, and vaccine design through a mix of collaborative and internal programs by applying the following business strategies:
- Provide epitope discovery and de-immunization services to researchers and developers in industry and academia.
- Establish collaborations with pharmaceutical, vaccine, and biotechnology companies focused on biological targets chosen by the collaborators.
- Conduct internal discovery and design efforts aimed at selected biological targets, retaining a larger economic interest in thesubsequently out-licensed lead candidates.
- Maintain technology leadership in both product development andrapid vaccine design capabilities through grant funded R&D programs.
Related Items (7)
|EpiVax to collaborate with pharmaceutical giant||12.04.09||Providence Journal|
|Annie De Groot, founder of Providence-based Epivax, proves the power of one person||10.01.09||Boston Herald|
|Can Higher Ed Boost Biotech Start-Ups In RI?||08.24.09||WRNI|
|New lab will research vaccines||02.24.09||Providence Journal|
|EpiVax founder to lead new university institute||02.14.09||Providence Business News|
|URI names EpiVax founder to head Institute for Immunology & Informatics||02.12.09||Providence Business News|
|Health is EpiVax’s work, giving||11.21.08||Mass High Tech|
Please help us to keep the information accurate and up-to-date.
Email us your edits, additions, and deletions. Thank you.